BLAINJECTIONINJECTABLE
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
5/8 — Partial
HADLIMA (adalimumab-bwwd) by Samsung Bioepis is tumor necrosis factor receptor blocking activity [moa]. Approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and 4 more indications. First approved in 2019.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HADLIMA (adalimumab-BWWD) is a monoclonal antibody biosimilar that blocks tumor necrosis factor (TNF), a key driver of inflammation. It treats 11 indications across rheumatology, gastroenterology, and dermatology, including rheumatoid arthritis, Crohn's disease, psoriasis, and uveitis. As a TNF-blocking biosimilar approved in 2019, it offers a lower-cost alternative to reference biologics in an increasingly crowded market.
$14KPart D
PeakHADLIMA is in peak lifecycle but captures minimal Part D volume ($14K from 12 claims in 2023), indicating limited market traction relative to originator adalimumab and competitor biosimilars; expect a lean commercial team focused on payer access and specialty pharmacy placement.
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications (7)
Worked on HADLIMA at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.